| 商品名称 | Sunlenca |
|---|---|
| 适用类别 | Human |
| 治疗领域 | HIV Infections |
| 通用名/非专利名称 | lenacapavir |
| 活性成分 | lenacapavir sodium |
| 产品号 | EMEA/H/C/005638 |
| 患者安全信息 | No |
| 许可状态 | Authorised |
| ATC编码 | J05AX |
| 是否额外监管 | Yes |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 2022/08/17 |
| 上市许可开发者/申请人/持有人 | Gilead Sciences Ireland Unlimited Company |
| 人用药物治疗学分组 | Antivirals for systemic use |
| 兽用药物治疗学分组 | |
| 审评意见日期 | 2022/06/23 |
| 欧盟委员会决定日期 | 2025/12/16 |
| 修订号 | 7 |
| 治疗适应症 | Sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4.2 and 5.1). Sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4.2 and 5.1). |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2022/06/22 |
| 最后更新日期 | 2025/12/16 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/sunlenca-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/sunlenca |